prikaz prve stranice dokumenta Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Pristup korisnicima matične ustanove
Znanstveni rad - Prikaz slučaja
Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Anti-Cancer Drugs, 29 (2018), 3; 281-285. https://doi.org/10.1097/CAD.0000000000000587
Drpa, Gordana; Sreter, Katherina B.; Manojlovic, Spomenka; Kukulj, Suzana

Citirajte ovaj rad

Drpa, G., Sreter, K. B., Manojlovic, S. i Kukulj, S. (2018). Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?. Anti-Cancer Drugs, 29. (3), 281-285. doi: 10.1097/CAD.0000000000000587

Drpa, Gordana, et al. "Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?." Anti-Cancer Drugs, vol. 29, br. 3, 2018, str. 281-285. https://doi.org/10.1097/CAD.0000000000000587

Drpa, Gordana, Katherina B. Sreter, Spomenka Manojlovic i Suzana Kukulj. "Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?." Anti-Cancer Drugs 29, br. 3 (2018): 281-285. https://doi.org/10.1097/CAD.0000000000000587

Drpa, G., et al. (2018) 'Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?', Anti-Cancer Drugs, 29(3), str. 281-285. doi: 10.1097/CAD.0000000000000587

Drpa G, Sreter KB, Manojlovic S, Kukulj S. Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?. Anti-Cancer Drugs [Internet]. 03.2018. [pristupljeno 26.10.2024.];29(3):281-285. doi: 10.1097/CAD.0000000000000587

G. Drpa, K. B. Sreter, S. Manojlovic i S. Kukulj, "Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?", Anti-Cancer Drugs, vol. 29, br. 3, str. 281-285, Ožujak 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:381374. [Citirano: 26.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:381374
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
AutorGordana Drpa
AutorKatherina B. Sreter
AutorSpomenka Manojlovic
AutorSuzana Kukulj
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Adenocarcinoma (AC) is the most common type of primary pulmonary malignancy. Lung carcinoid, however, is a rare neuroendocrine tumor. Their coexistence is extremely uncommon. We report the unique case of synchronous advanced lung AC of the right upper lobe (stage IIIB) and typical endobronchial carcinoid tumor in the contralateral lower lobe in a 49-year-old white female who had never smoked. PET-computed tomography scan revealed a fluorine-18-fluorodeoxyglucose-avid AC lesion, whereas the carcinoid tumor was fluorine-18-fluorodeoxyglucose occult. After two lines of platinum-based combination chemotherapies and radiotherapy, the AC progressed, and oral tyrosine kinase inhibitor therapy with erlotinib was initiated in third line. On erlotinib, the AC remained stable for 50 months until disease progression, whereas the carcinoid completely regressed. Molecular testing of the rebronchoscopied AC revealed an exon 19 deletion mutation in the epidermal growth factor receptor (EGFR) gene, whereas the carcinoid was retrospectively EGFR mutation negative. The patient eventually succumbed to ileus caused by intra-abdominal spread of disease, surviving a remarkable 80 months with good performance status throughout most of the follow-up period. To the best of our knowledge, this is the first reported case of synchronous primary lung cancers with different EGFR mutation status, describing an unexpected response of an EGFR-wild-type carcinoid to third-line erlotinib.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaAnti-Cancer Drugs
Brojčani podacivol. 29, br. 3, str. 281-285
p-ISSN0959-4973
DOIhttps://doi.org/10.1097/CAD.0000000000000587
URN:NBNurn:nbn:hr:220:381374
Datum objave publikacije2018-03
URL dokumentahttps://journals.lww.com/00001813-201803000-00010
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-09-20 10:21:23